Besançon, Alix
Goncalves, Tania
Valette, Fabrice
Mary, Caroline
Vanhove, Bernard
Chatenoud, Lucienne
You, Sylvaine
Funding for this research was provided by:
FP7 Health (281493)
Institut National de la Santé et de la Recherche Médicale (Institutional funding)
Université Paris Descartes (Institutional funding)
Fondation Day Solvay
Société Française d’Endocrinologie et Diabétologie Pédiatrique
Article History
Received: 29 January 2018
Accepted: 19 April 2018
First Online: 29 May 2018
Duality of interest
: BV and CM are current employees of OSE Immunotherapeutics (formerly Effimune SAS). The pegylated anti-CD28 Fab′ antibody fragment (PV1-PEG) is the property of OSE Immunotherapeutics, Nantes, France. AB, FV, TG, LC and SY declare no commercial or financial conflict of interest. The study sponsor was not involved in: the design of the study; the collection, analysis or interpretation of data; writing the report; or the decision to submit the report for publication.